An observational study in First Episose Psychosis, Metabolic Disease and Psychosis; Episode, sponsored by Université de Sherbrooke. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Université de Sherbrooke · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Metabolic Diseases with a site in Canada — 15 open to participants now, 24 under way, 8 of them phase 3. Metabolic Diseases · Canada.
Among the 67 studies in Metabolic Diseases with a site in Canada, this one is one of 10 that started in 2024, is one of 9 observational ones, reaches primary completion later than 16 of the 23 other live ones, and was the 63rd registered.
765 studies on the registry are indexed under Metabolic Diseases; 194 are open to participants now.
Browse Metabolic Diseases studies →15 of the 67 studies in Metabolic Diseases with a site in Canada are open now. Recruiting first, the newest first:
CHU de Quebec-Universite Laval · Sites in Canada
Ages 18–80
Dr. B. Catharine. Craven · Sites in Canada
Ages 18–75
Pfizer · Sites in Canada, United States, Brazil and 8 more countries
Ages 18+
Kyowa Kirin Co., Ltd. · Sites in Canada, United States, France and 2 more countries
Ages 18–65
Hoffmann-La Roche · Sites in Canada, United States, Argentina and 22 more countries
Ages 18–75
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 135 Metabolic Diseases studies recruiting now, 47 (35%) set no upper age limit and 64 (47%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 15 · Phase 3 23
First in 2001; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 18 is below the median of 210 across 213 observational studies indexed under Metabolic Diseases.
Median enrollment 74 across the 58 interventional studies, 18 across the 9 observational. Of the 40 that completed or were terminated, 20 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 67 have an industry lead sponsor. The 10 most frequent:
Université de Sherbrooke is the lead sponsor of 298 studies on the registry; 67 are open to participants now.
Université de Sherbrooke has 1 study filed under Metabolic Diseases — fewer than ten, so there is no comparison to draw.
7 of the studies in Metabolic Diseases with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT00920972Washington University School of MedicineCampath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases | 2026-12 |
| NCT07588503Dr. B. Catharine. CravenFES Cycling With BFR in the Spinal Cord Injury Population | 2027-01-01 |
| NCT04159103ModernaTX, Inc.Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia | 2027-08-31 |
| NCT05910840Anne-Sophie BrazeauSupport-t Online Training in Youth Living With Type 1 Diabetes Transitioning to Adult Care | 2027-09-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 67 studies in Metabolic Diseases with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to the early impacts of psychosis and antipsychotic medications on brain metabolism in young adults recently diagnosed with a first episode of psychosis.
The main question aims to evaluate the effect of 4 to 6 weeks of antipsychotic medication on brain metabolism measured by PET scan (cerebral uptake of 11C-Acetoacetate + 18 Fluorodeoxyglucose).
Participants will undergo a multimodal imaging protocol with other measures of psychopathology (e.g., cognition, depressive symptoms, etc.) and (metabolic marker, inflammation, etc).
Individuals aged 18 to 35 from the Estrie region who have been evaluated by the PEP team and wish to start an antipsychotic (AP) for the treatment of a first episode of psychosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Individuals aged 18 to 35 from the Estrie region who have been evaluated by the "PEP team" (First episode psychosis intervention Team of the pschiatric department of the CIUSSS de l'Estrie-CHUS) and wish to start an antipsychotic (AP) for the treatment of a first episode of psychosis.
Drug: Antipsychotic drugs
Any Antipsychotic drugs prescripbe as standrd of care for this specific populaton
Cerebral metabolic rate of glucose and acetotacetate
Cerebral metabolic rate of glucose and acetotacetate(μmol/100 g/min) quantified with PET scan with 18F-FDG tracer and 11C-AcAc
Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks
Net inflow of glucose and acetoacetate
Net inflow of glucose and acetoacetate (k) as measured by PET scan with 18F-FDG and 11C-AcAc traceur (Kglu and Kacac, min-1)
Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks
% of change in Brief Psychiatric Rating Scale
% of change in the Brief psychiatric Rating Scale (raw score after/raw score before\*100)
Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks
Concentration of glucose
Concentration of glucose measure in fasting plasma
Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks
Concentration of insuline
Concentration of insulinemeasure in fasting plasma
Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks
Concentration of Hemoglobin A1C
Concentration of HbA1C measured in fasting plasma
Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks
Global brain volume measured by MRI
Global brain volumes measured as global brain volumes (ml) measured by MRI
Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks
Thicknesses of the cerebral cortex
Thicknesses of the cerebral cortex (mm) measured by MRI
Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks
Depression status measured by the score of "Calgary Depression Scale for Schizophrenia
Score of "Calgary Depression Scale for Schizophrenia" (CDSS) . Min score 0, maximum score 27 with worsening of the patient condition with hight value
Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks
Functionning level measured by the score of the Global Assessment of functionning
Score of the "Global Assessment of functionning (GAF). Min score 0, maximum score 100, with worsening of the patient condition with higher value
Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks
Side effet score measured by the Side Effect Rating Scale
Score on the "Side Effect Rating Scale" UKU. Min score 0, maximum score 135 (female) 129 (male), with worsening of the side effect with higher value
Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks
Alcohol consumption measured by the score of the Alcohol Use Disorders Identification Test -AUDIT
Alcoohol consumption as measured by the score of the Alcohol Use Disorders Identification Test AUDIT. Min score 0, maximum score 40, with higher alcool consumption with higher value of the score
Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks
Drug consumption measured by the score of the Drug Use Disorders Identification Test -DUDIT
Drug consumption as measured by the score of the Drug Use Disorders Identification Test DUDIT. Min score 0, maximum score 40, with higher alcool consumption with higher value of the score
Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks
Average weekly hours of sport/exercise per day
Average weekly hours of sport/exercise per day" as measured by question 4 of the Simple Physical Activity questionnaire SIMPAQ (hour)
Time frame: BEFORE introduction of antipsychotic medicationand AFTER 4 to 6 weeks
Started Nov 2024 (actual). Primary completion is estimated for Dec 2027, 37 months after the start.
Of 89 non-industry observational studies under Metabolic Diseases, half reached primary completion within 135 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 339. This study's planned 37 months is below that.
Counting every sponsor, half of 101 studies reached it within 135 months; a quarter within 23 and three quarters within 339.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Nov 2026 → Dec 2027 and completion Jun 2027 → Jun 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.